Status:
COMPLETED
A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
This study evaluates a new formulation of insulin lispro, LY900014, a drug that lowers blood sugar. It is administered by injection into the vein and under the skin of the abdomen, thigh and arm. The...
Eligibility Criteria
Inclusion
- Overtly healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)
- Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)
- Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study
- Are nonsmokers, have not smoked for at least 6 months prior to entering the study
Exclusion
- Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
- Have previously participated or withdrawn from this study
- Had blood loss of more than 450 milliliters (mL) within the last 3 months
Key Trial Info
Start Date :
August 14 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2017
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT03232983
Start Date
August 14 2017
End Date
November 9 2017
Last Update
April 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Singapore, Singapore, 117597